<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461861</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00031146</org_study_id>
    <secondary_id>R21AG056882-01</secondary_id>
    <nct_id>NCT03461861</nct_id>
  </id_info>
  <brief_title>Network-Level Mechanisms for Preclinical Alzheimer's Disease Development</brief_title>
  <official_title>Network-Level Mechanisms for Preclinical Alzheimer's Disease Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam
      extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus
      in normal, healthy adults who are APOE 4 carriers. The investigators will compare the results
      to normal, healthy adults who are APOE 4 non-carriers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators want to find out whether the use of a perturbation, such as
      AGB101 low dose of levetiracetam extended release formulation, in healthy adults with the
      Apolipoprotein e4 gene (APOE 4) can reduce abnormal hippocampal network activity. The
      investigators also want to study whether this low dose of LEV can improve memory function.

      Generic levetiracetam is a type of drug called an anti-epileptic or anti-seizure medication.
      It is FDA approved worldwide for adults and children as young as one month with seizures. It
      is a generic drug used in long-term epilepsy treatment. It is relatively safe and has an
      acceptable side-effect profile.

      AGB101 has been developed as a novel extended release formulation of low dose levetiracetam
      (below clinically marketed doses for epilepsy) for slowing the progression of amnestic mild
      cognitive impairment.

      It is known that age and the APOE 4 gene are important risk factors for late-onset
      Alzheimer's disease. Further studies have shown that cognitively normal, older adults with
      the APOE 4 gene have more hyperfunctional brain network activity, increased alpha beta
      accumulation, decreased memory function, and decreased brain volume, which is consistent with
      Alzheimer's disease patterns.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19
  </why_stopped>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled crossover study in which a low dose of AGB101 (220mg QD) or placebo will be administered to 50 healthy 55-75-year-old subjects (comprising 25 APOE 4 carriers and 25 noncarriers), with the order of treatments counterbalanced in a within-subject crossover design.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional connectivity strengths of neural networks</measure>
    <time_frame>At the baseline and 2 weeks after treatment</time_frame>
    <description>The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes before and after the AGB101 perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions and the maps of the functional connectivity strengths.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rey Auditory Verbal Learning Test (AVLT)</measure>
    <time_frame>At the baseline and 2 weeks after treatment</time_frame>
    <description>AVLT will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded and later integrated with LMT score to provide the composite EM score. The EM score for a subject is a standardized z-score converted from AVLT and LMT scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logical memory test (LMT)</measure>
    <time_frame>At the baseline and 2 weeks after treatment</time_frame>
    <description>LMT will be employed to measure the episodic memory changes before and after AGB101 treatment. The LMT score will be recorded and later integrated with AVLT score to provide the composite EM score. The EM score for a subject is a standardized z-score converted from AVLT and LMT scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>APOE 4</condition>
  <arm_group>
    <arm_group_label>AGB101 220 mg, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then AGB101 220 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGB101 220 mg</intervention_name>
    <description>AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.</description>
    <arm_group_label>AGB101 220 mg, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then AGB101 220 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, oral capsule given once-daily.</description>
    <arm_group_label>AGB101 220 mg, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then AGB101 220 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fluent in English

          -  At least eight (8) years of education

          -  Geriatric Depression Scale (GDS) (62) score &lt; 6

          -  Hachinski Ischemic Score ≤ 4

          -  Normal general cognitive function as well as 1) normal memory function, documented by
             MOCA score of 23 or greater, and a RBANS Delayed Memory Index score of 85 or greater.

        Exclusion Criteria:

          -  Neurological disease, such as Parkinson's disease, multi-infarct dementia,
             Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive
             supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a
             history of significant head trauma or known structural brain abnormalities

          -  Major psychiatric disease or chronic unstable medical conditions

          -  History of drug abuse

          -  History of alcohol abuse (4 or greater drinks per day on average)

          -  Unable to complete MRI scans (no Pacemaker/Defibrillator)

          -  Known clinically significant abnormalities in B12 or thyroid function tests

          -  End Stage Renal Disease (ESRD)

          -  Hemodialysis (HD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi-Jiang Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert &amp; The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9. Epub 2003 Dec 19.</citation>
    <PMID>14688411</PMID>
  </reference>
  <reference>
    <citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7209-14. doi: 10.1073/pnas.0811879106. Epub 2009 Apr 8.</citation>
    <PMID>19357304</PMID>
  </reference>
  <reference>
    <citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010 Mar 15;67(6):584-7. doi: 10.1016/j.biopsych.2009.08.024. Epub 2009 Oct 14.</citation>
    <PMID>19833321</PMID>
  </reference>
  <reference>
    <citation>Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Singh SP, Franczak MB, Goveas JS, Li SJ. Aberrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged APOE4 carriers. Cortex. 2014 Aug;57:167-76. doi: 10.1016/j.cortex.2014.04.006. Epub 2014 Apr 30.</citation>
    <PMID>24905971</PMID>
  </reference>
  <reference>
    <citation>Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, Liu C, Dixit S, Benzinger T, Fagan A, Goate A, Mintun MA. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci. 2010 Dec 15;30(50):17035-40. doi: 10.1523/JNEUROSCI.3987-10.2010.</citation>
    <PMID>21159973</PMID>
  </reference>
  <reference>
    <citation>Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010 Mar;35(4):1016-25. doi: 10.1038/npp.2009.207. Epub 2009 Dec 23.</citation>
    <PMID>20032967</PMID>
  </reference>
  <reference>
    <citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.</citation>
    <PMID>22869752</PMID>
  </reference>
  <reference>
    <citation>Devi L, Ohno M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. Neurobiol Learn Mem. 2013 May;102:7-11. doi: 10.1016/j.nlm.2013.02.001. Epub 2013 Feb 13.</citation>
    <PMID>23416036</PMID>
  </reference>
  <reference>
    <citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012 May 10;74(3):467-74. doi: 10.1016/j.neuron.2012.03.023.</citation>
    <PMID>22578498</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013 Sep 1;70(9):1158-66. doi: 10.1001/jamaneurol.2013.136.</citation>
    <PMID>23835471</PMID>
  </reference>
  <reference>
    <citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 Sep 6;55(5):697-711.</citation>
    <PMID>17785178</PMID>
  </reference>
  <reference>
    <citation>Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis. 2011 Feb 24;2011:726197. doi: 10.4061/2011/726197.</citation>
    <PMID>21423560</PMID>
  </reference>
  <reference>
    <citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004 Jul;56(1):27-35.</citation>
    <PMID>15236399</PMID>
  </reference>
  <reference>
    <citation>Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem. 2002 Sep 6;277(36):33012-7. Epub 2002 Jun 14.</citation>
    <PMID>12068009</PMID>
  </reference>
  <reference>
    <citation>Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci. 2010 Oct 27;30(43):14299-304. doi: 10.1523/JNEUROSCI.3383-10.2010.</citation>
    <PMID>20980585</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Shi-Jiang Li, PhD</investigator_full_name>
    <investigator_title>Professor of Biophysics</investigator_title>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Adult</keyword>
  <keyword>Normal Memory</keyword>
  <keyword>APOE 4</keyword>
  <keyword>Brain</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Hippocampus</keyword>
  <keyword>Genetic testing</keyword>
  <keyword>Dementia</keyword>
  <keyword>AGB101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

